John M. Leonard - Jan 1, 2023 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
President and CEO, Director
Signature
James Basta, attorney-in-fact
Stock symbol
NTLA
Transactions as of
Jan 1, 2023
Transactions value $
$0
Form type
4
Date filed
1/4/2023, 07:36 PM
Previous filing
May 13, 2022
Next filing
Jan 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Options Exercise +7.85K +1.03% 773K Jan 1, 2023 Direct F1
holding NTLA Common Stock 58.4K Jan 1, 2023 By Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Restricted Stock Unit Options Exercise $0 -7.85K -33.33% $0.00 15.7K Jan 1, 2023 Common Stock 7.85K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2 Shares held by the John M. Leonard 2015 Irrevocable Trust.
F3 On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.